Regen BioPharma Inc (RGBP)

[art35]

MICRO CAP INSIDERSMALL CAPSSTREET WATCH

Regen BioPharma Inc (OTCMKTS: RGBP) Powerful Run Brewing As Company Looks to Crush the Competition (HemaXellerate)

By Boe Rimes
June 14, 2021


Regen BioPharma Inc (OTCMKTS: RGBP) is making an explosive move up the charts since reversing up off its base at the $0.01 mark.

Microcapdaily initially covered RGBP in April of htis year when the stock skyrocketed from triple zeroes to highs of $0.081 after the Regen and its subsidiary KLS have entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021.

The License IP consists of antigen specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.

The Company is currently in the process of updating its filings and preparing outstanding 10Q and 10k reports in order to up list to fully reporting otcqb “pink current” tier.

After a brief respites RGPB is making a power house move move up the charts again looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars.

RGBP is in beast mode right now and is the most talked about small cap stock; a break over $0.082 and its blue skies ahead. RGBP buyout rumors abound; according to many investors It appears there may be a Potential Merger Acquisition looming with Precigen OR another Big Pharma and if so it would make perfect sense for the following reasons.

The CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $1.3B and has an extensive clinical trials pipeline in Immunology-Oncology that includes development of mRNA vaccines therapies.

https://precigen.com/about. Regenis in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that RGBP is in. 100% identical including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP OR does a Merger Acquisition and IMO the motive to do this are the numerous valuable Patents RGBP owns that have Billion Dollar Market Capacity.
Koos is presently on an aggressive campaign to pull everything together about RGBP in the shortest amount of time to apparently ready the company for SALE! If you look closely at his recent actions it points to this.